Compare Core Scientific Inc (CORZ) vs FMC Corp (FMC) Price & Performance

Core Scientific (CORZ) trades at $15.36, down 3.64% on the day, with bearish technical signals and negative earnings momentum. The company reported a net loss of $288.62 million in 2025 with revenue of $319.02 million, resulting in a -324.9% net income margin. Despite financial challenges, analyst sentiment remains overwhelmingly positive with 19 buy ratings and a $32.75 consensus price target, representing significant upside potential from current levels.

The stock presents a high-risk, high-reward opportunity with strong Wall Street support but substantial fundamental challenges. Positive catalysts include the AI data center transition and insider buying, while risks include persistent losses, heavy capital expenditures, and competitive pressures in the digital infrastructure space.

FMC trades at $8.92, down 1.87% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows weak profitability with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though recent quarterly EPS beats offer some optimism. Analyst consensus is divided with a near-even split between Buy and Hold ratings, and a $14.60 price target suggests significant upside from current levels. Recent news highlights regulatory progress for rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group.

The outlook for FMC hinges on successful deleveraging and product approvals, but high debt and cyclical industry pressures pose substantial risks. While valuation ratios like P/S of 0.34 appear attractive, persistent negative margins and volatile cash flows warrant caution. The stock presents a speculative opportunity for investors betting on a turnaround, but near-term headwinds in the agricultural sector may limit upside.